Vectura Group plc (LSE: VEC) (“Vectura”), an industry-leading inhalation CDMO, announces that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline’s (GSK) motions for judgment as a matter of law, a new trial on infringement and for a new trial on damages in litigation concerning Vectura’s US patent 8303991. The United States Court of Appeals for the Federal Circuit has therefore upheld the District Court of Delaware ruling on post-trial motions.
In September 2019, the District Court of Delaware issued the following ruling on the parties’ post-trial motions:
- Award of US$89.7m in damages to Vectura on May 3, 2019 upheld
- Ongoing royalties of 3% on US sales of certain infringing GSK Ellipta® products
- Supplemental damages based on GSK’s infringing sales of approximately US$10.5m
- Pre-judgment interest at the prime rate of approximately US$6.7m
GSK has 30 days to file a petition for rehearing.
For the full update, click here.